Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Anesiva, Inc.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of a single intraoperative dose of 4975 in patients undergoing primary unilateral total hip arthroplasty
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged 18 to 85 years with an American Society of Anesthesiologists (ASA) status of I, II, III
Planning to undergo unilateral THA
In good health and capable of undergoing THA with spinal block and sedation anesthesia
No additional planned surgeries during the course of the trial
Willing and able to complete the study procedures and pain scales and to communicate meaningfully in English
You may not be if
A body mass index greater than 40
Known bleeding disorder or is taking agents affecting coagulation preoperatively
A medical condition that could adversely impact the patient's participation, safety, or conduct of the study
Diabetes mellitus with a known HbA1C\>9.5 or a history of prolonged uncontrolled diabetes
Previous hip arthroplasty of the same hip
Participated in another clinical trial within 30 days of the planned hip surgery
